Vera Therapeutics Q3 EPS misses estimates

Reuters

11/05

Vera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 EPS misses estimates

Overview

Vera Therapeutics Q3 net loss and EPS miss analyst expectations
Company expects BLA submission for atacicept in Q4 2025
Vera maintains strong cash position, funding operations through potential atacicept launch

Outlook

Company expects to submit BLA for atacicept to FDA in Q4 2025
Vera anticipates potential U.S. launch of atacicept in 2026
Company expects initial PIONEER trial results in Q4 2025

Result Drivers

CLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for atacicept

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Miss	-$1.26	-$1.13 (12 Analysts)
Q3 Net Income	Miss	-$80.29 mln	-$75.26 mln (10 Analysts)
Q3 Operating Income	Miss	-$83.93 mln	-$75.62 mln (11 Analysts)
Q3 Operating Expenses		$83.93 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vera Therapeutics Inc is $60.00, about 59.4% above its November 4 closing price of $24.35

Press Release: ID:nGNX7LgC7F

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581542722"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581542722\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581542722?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581542722","market":"us","top_or_hot":-1,"title":"Vera Therapeutics Q3 EPS misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 EPS misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vera Therapeutics Q3 net loss and EPS miss analyst expectations</p></li><li><p>Company expects BLA submission for atacicept in Q4 2025</p></li><li><p>Vera maintains strong cash position, funding operations through potential atacicept launch</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to submit BLA for atacicept to FDA in Q4 2025</p></li><li><p>Vera anticipates potential U.S. launch of atacicept in 2026</p></li><li><p>Company expects initial PIONEER trial results in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for atacicept</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Miss</p></td><td><p>-$1.26</p></td><td><p>-$1.13 (12 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$80.29 mln</p></td><td><p>-$75.26 mln (10 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Miss</p></td><td><p>-$83.93 mln</p></td><td><p>-$75.62 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$83.93 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vera Therapeutics Inc is $60.00, about 59.4% above its November 4 closing price of $24.35</p></li></ul><p>Press Release: <span>ID:nGNX7LgC7F</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics Q3 EPS misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics Q3 EPS misses estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 20:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 EPS misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vera Therapeutics Q3 net loss and EPS miss analyst expectations</p></li><li><p>Company expects BLA submission for atacicept in Q4 2025</p></li><li><p>Vera maintains strong cash position, funding operations through potential atacicept launch</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to submit BLA for atacicept to FDA in Q4 2025</p></li><li><p>Vera anticipates potential U.S. launch of atacicept in 2026</p></li><li><p>Company expects initial PIONEER trial results in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for atacicept</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Miss</p></td><td><p>-$1.26</p></td><td><p>-$1.13 (12 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$80.29 mln</p></td><td><p>-$75.26 mln (10 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Miss</p></td><td><p>-$83.93 mln</p></td><td><p>-$75.62 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$83.93 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vera Therapeutics Inc is $60.00, about 59.4% above its November 4 closing price of $24.35</p></li></ul><p>Press Release: <span>ID:nGNX7LgC7F</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0N2:1","article_id":"2581542722","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581542722","pubTimestamp":1762346203,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vera Therapeutics Q3 EPS misses estimatesOverviewVera Therapeutics Q3 net loss and EPS miss analyst expectationsCompany expects BLA submission for atacicept in Q4 2025Vera maintains strong cash positi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","VERA":"Vera Therapeutics, Inc."},"translate_title":"Vera Therapeutics第三季度每股收益低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":0.9},"content_text":"Vera Therapeutics Q3 EPS misses estimatesOverviewVera Therapeutics Q3 net loss and EPS miss analyst expectationsCompany expects BLA submission for atacicept in Q4 2025Vera maintains strong cash position, funding operations through potential atacicept launchOutlookCompany expects to submit BLA for atacicept to FDA in Q4 2025Vera anticipates potential U.S. launch of atacicept in 2026Company expects initial PIONEER trial results in Q4 2025Result DriversCLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for ataciceptKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSMiss-$1.26-$1.13 (12 Analysts)Q3 Net IncomeMiss-$80.29 mln-$75.26 mln (10 Analysts)Q3 Operating IncomeMiss-$83.93 mln-$75.62 mln (11 Analysts)Q3 Operating Expenses$83.93 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Vera Therapeutics Inc is $60.00, about 59.4% above its November 4 closing price of $24.35Press Release: ID:nGNX7LgC7FFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}